



Provisional Notice of the End Result

of the public tender offer by

CSL Behring AG, Berne, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

Vifor Pharma Ltd., St. Gallen, Switzerland

On January 18, 2022, CSL Behring AG (the **Offeror**) published the offer prospectus (the **Offer Prospectus**) for its public tender offer according to articles 125 *et seq.* FMIA (the **Offer**) for all publicly held registered shares of Vifor Pharma Ltd. (**Vifor**) with a nominal value of CHF 0.01 each (each a **Vifor Share**). The offer price for each Vifor Share is USD 179.25 in cash, less the gross amount of any dilutive effects in respect of the Vifor Shares prior to the Settlement (as further described in the Offer Prospectus).

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

Provisional End Result

As of the end of the Additional Acceptance Period on March 22, 2022, 4:00 p.m. Swiss time, and based on preliminary figures, the participation of the Offeror and the persons acting in concert with the Offeror is 61,096,902 Vifor Shares in aggregate, corresponding to 94.00% of the issued share capital and voting rights of Vifor (*participation rate*). 61,025,396 Vifor Shares were tendered into the Offer until the end of the Additional Acceptance Period, corresponding to 93.99% of all Vifor Shares to which the Offer relates as of the end of the Additional Acceptance Period (*success rate*).

The following overview summarizes the end result based on preliminary figures:

	Number of Vifor Shares	In % of share capital/voting rights (participation rate)	In % of Vifor Shares to which the Offer relates (success rate)
Vifor Shares tendered into the Offer	61,025,396	93.89%	93.99%
Vifor Shares held by the Offeror and the persons acting in concert with the Offeror as at the end of the Additional Acceptance Period*	71,506	0.11%	
Provisional end result	61,096,902	94.00%	

* Consisting entirely of treasury shares held by Vifor and its subsidiaries. The Offeror and the persons acting in concert with the Offeror (other than Vifor and its subsidiaries) held no Vifor Shares as at the end of the Additional Acceptance Period.

Definitive Notice of the End Result

The end result announced in this notice is preliminary. The definitive notice of the end result is expected to be published on March 28, 2022 and will contain statements as to the satisfaction of the Offer Conditions and as to the Settlement.

Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus may be obtained free of charge in German, French and English from Credit Suisse AG (e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and other information concerning the Offer are also available at www.csltransaction.com.

Vifor Pharma Ltd.	Swiss securities number	ISIN	Ticker symbol
Vifor Shares not tendered (first trading line)	36 474 934	CH036 474 934 8	VIFN
Vifor Shares tendered (second trading line)	115 606 016	CH115 606 016 7	VIFNE
Vifor Shares tendered for USD/CHF Conversion Facility (third line, not traded)	115 606 017	CH115 606 017 5	--

March 23, 2022

Lead Financial Advisor
PJT Partners

Financial Advisor
BofA SECURITIES

Financial Advisor
Goldman Sachs

Financial Advisor and Offer Manager
Credit Suisse